Complete financial analysis of Notable Labs, Ltd. (NTBL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Notable Labs, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Theralink Technologies, Inc. (THER) Income Statement Analysis – Financial Results
- ADF Group Inc. (DRX.TO) Income Statement Analysis – Financial Results
- TOYAM SPORTS LIMITED (TOYAMSL.BO) Income Statement Analysis – Financial Results
- Doric Nimrod Air Three Limited (DNA3.L) Income Statement Analysis – Financial Results
- FB Bancorp, Inc. Common Stock (FBLA) Income Statement Analysis – Financial Results
Notable Labs, Ltd. (NTBL)
About Notable Labs, Ltd.
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 310.00K | 8.00K | 285.00K | 922.00K | 562.00K | 585.00K | 13.86M | 0.00 | 0.00 |
| Cost of Revenue | 197.00K | 1.16M | 1.62M | 1.59M | 1.44M | 1.39M | 496.00K | 130.00K | 122.00K |
| Gross Profit | 113.00K | -1.15M | -1.34M | -666.00K | -879.00K | -806.00K | 13.37M | -130.00K | -122.00K |
| Gross Profit Ratio | 36.45% | -14,425.00% | -468.77% | -72.23% | -156.41% | -137.78% | 96.42% | 0.00% | 0.00% |
| Research & Development | 4.71M | 7.78M | 11.47M | 18.46M | 13.50M | 16.87M | 19.85M | 14.06M | 12.96M |
| General & Administrative | 10.06M | 5.16M | 5.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.06M | 5.16M | 5.73M | 5.36M | 5.71M | 5.55M | 6.36M | 3.79M | 3.64M |
| Other Expenses | -1.56M | -1.48M | 862.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.77M | 12.93M | 17.20M | 23.82M | 19.20M | 22.42M | 26.21M | 17.85M | 16.60M |
| Cost & Expenses | 14.97M | 12.93M | 17.20M | 25.41M | 20.64M | 23.81M | 26.71M | 17.98M | 16.72M |
| Interest Income | 0.00 | 0.00 | 0.00 | 363.00K | 870.00K | 908.00K | 335.00K | 263.00K | 100.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 105.00K | 184.00K | 37.00K | 27.00K | 12.00K | 16.00K |
| Depreciation & Amortization | 257.00K | 1.06M | 1.26M | 1.19M | 1.22M | 1.16M | 156.00K | 130.00K | 122.00K |
| EBITDA | -14.40M | -12.60M | -16.59M | -23.29M | -18.86M | -22.07M | -12.69M | -17.85M | -16.60M |
| EBITDA Ratio | -6,241.94% | -157,512.50% | -5,820.35% | -2,525.92% | -3,356.41% | -3,771.97% | -91.52% | 0.00% | 0.00% |
| Operating Income | -14.66M | -12.92M | -16.91M | -24.48M | -20.08M | -23.22M | -12.84M | -17.98M | -16.72M |
| Operating Income Ratio | -4,728.06% | -161,550.00% | -5,934.74% | -2,655.42% | -3,573.31% | -3,969.57% | -92.64% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.39M | -1.48M | 862.00K | 258.00K | 686.00K | 2.76M | 2.71M | 1.97M | 1.83M |
| Income Before Tax | -11.26M | -14.41M | -16.05M | -24.23M | -19.40M | -20.46M | -10.14M | -16.00M | -14.89M |
| Income Before Tax Ratio | -3,633.55% | -180,087.50% | -5,632.28% | -2,627.44% | -3,451.25% | -3,497.09% | -73.12% | 0.00% | 0.00% |
| Income Tax Expense | -4.95M | 94.52K | 89.44K | -1.00 | -1.00 | -1.00 | 0.00 | -1.00 | 0.00 |
| Net Income | -11.26M | -14.41M | -16.05M | -24.23M | -19.40M | -20.46M | -10.14M | -16.00M | -14.89M |
| Net Income Ratio | -3,633.55% | -180,087.50% | -5,632.28% | -2,627.44% | -3,451.25% | -3,497.09% | -73.12% | 0.00% | 0.00% |
| EPS | -5.03 | -6.50 | -9.28 | -19.42 | -18.92 | -0.62 | -0.37 | -0.64 | -0.73 |
| EPS Diluted | -5.03 | -6.50 | -9.28 | -19.42 | -18.92 | -0.62 | -0.37 | -0.64 | -0.73 |
| Weighted Avg Shares Out | 2.24M | 2.22M | 1.73M | 1.25M | 1.03M | 32.97M | 27.40M | 24.97M | 20.31M |
| Weighted Avg Shares Out (Dil) | 2.24M | 2.22M | 1.73M | 1.25M | 1.03M | 32.97M | 27.40M | 24.97M | 20.31M |
Notable Labs to Present Data on September 4th at SOHO 2024
Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd.
Notable Labs Announces CEO Transition
Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd.
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now
Notable Labs (NTBL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near...
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced that Thomas...
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?
Notable Labs (NTBL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Notable Labs Reports 2023 Financial Results and Provides a Business Update
FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), reported financial results for the...
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented...
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented...
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that...
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that...
Source: https://incomestatements.info
Category: Stock Reports